Greenovation Biotech GmbH announced that it has dosed the first patient in a phase 1b study of its biopharmaceutical, moss-aGal, in adults with the inherited disorder, Fabry disease. Moss-aGal is a recombinant form of human alpha-galactosidase. It has been developed by Greenovation as an enzyme replacement therapy (ERT) for patients with Fabry disease, a genetic lysosomal storage disorder. The privately owned company Greenovation was founded by Prof. Dr. Gunter Neuhaus and Prof. Dr. Ralf Reski and develops next-generation therapeutics using its proprietary BryoTechnology platform. The company aims to optimize the production of highly-efficient glycoproteins for proprietary and customer use.
whole media release at Greenovation